Second chance for grantees

Leidos promises a second life for unfunded NIH proposals

NIH has launched a pilot program with Leidos Holdings Inc. (NYSE:LDOS) to answer the question: is there life after grant rejection?

The academic community has long groused about funding limitations through NIH, and even with the $2 billion

Read the full 376 word article

User Sign In